Rushad Patell, MBBS

Assistant Professor
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States

Rushad Patell is a staff hematologist at Beth Israel Deaconess Medical Center in Boston, USA and an Assistant Professor of Medicine at Harvard Medical School, Boston, MA. His area of research focus includes thrombotic and bleeding disorders in high risk populations including patients with malignancy and COVID-19. He also has a dedicated interest in graduate medical education and mentoring trainees in hematology at different stages of training.

Presentation(s):

• OC 12.1 - Unraveling CD200R1 as a novel mechanism of thromboinflammation in cancer

  Sunday, June 23, 2024
  09:30 – 09:45 ICT

• PB0419 - Artificial Intelligence and Venous Thromboembolism: Talking to the Experts

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0389 - Estimating in hospital and post-discharge venous and arterial thrombotic events in patients with COVID-19

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• SSC 10.3 - Outcomes of Splanchnic Vein Thrombosis in Patients with Myeloproliferative Neoplasms

  Sunday, June 23, 2024
  16:47 – 16:59 ICT

• OC 33.6 - Acquired platelet disorders

  Monday, June 24, 2024
  09:30 – 10:45 ICT

• PB0939 - A Multicenter Study Evaluating the Effect of Timing of Mechanical Thrombectomy in Improvement of Right Ventricular Function for Intermediate Risk Pulmonary Embolism

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB1471 - A Multidisciplinary Splanchnic Vein Thrombosis Clinic: Experiences from the First Year

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB0992 - Impact of thrombocytopenia on bleeding and thrombotic complications in patients with atrial fibrillation starting anticoagulation: a time varying analysis.

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1133 - Validating the JAKPOT prediction rule for identifying which patients with erythrocytosis are unlikely to have a JAK2 mutation

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• OC 68.5 - Platelet Drp1 phosphorylation is controlled by a dual phosphorylation pathway requiring dense granule release: Implications for evaluating antiplatelet therapy

  Tuesday, June 25, 2024
  15:45 – 16:00 ICT